Trial Profile

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Polatuzumab vedotin (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
Indications B-cell lymphoma; Diffuse large B cell lymphoma; T-cell lymphoma
Focus Registrational; Therapeutic Use
Acronyms POLARIX
Sponsors Chugai Pharmaceutical; Genentech; Roche

19 May 2026 According to a Roche media release, data form this trial will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held 29 May to 2 June in Chicago.
08 May 2026 Actual primary completion date changed to 30 Apr 2026.
08 May 2026 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com